文拉法辛联合喹硫平治疗焦虑障碍疗效观察

Clinical study of venlafaxine combined with quetiapine in the treatment of anxiety disorder

目的探讨文拉法辛联合喹硫平治疗焦虑障碍的安全性和疗效。方法将符合入组标准的焦虑障碍患者60例,随机分配到文拉法辛合用喹硫平组(研究组)和单用文拉法辛组(对照组)。于治疗前及治疗1周、2周、4周、6周末分别用汉密尔顿焦虑量表(HAMA,14项)及副反应量表(TESS)评定治疗效果。结果两组在治疗后2周、4周、6周末时HAMA总分及减分率的差异均有统计学意义(P<0.05),两组间治愈率、有效率的差异也有统计学意义(P<0.05),药物不良反应两组间无明显差异(P>0.05)。结论文拉法辛联合喹硫平治疗焦虑障碍疗效要明显优于单用文拉法辛,不良反应无明显增多。

Objective To investigate the efficacy and safety of venlafaxine combined with Quetiapine in the treatment of anxiety disorder. Methods 60 patients were randomly divided into 6 weeks of quetiapine combined releasing venlafaxine or releasing venlafaxine monotherapy group. The efficacy and adverse effect of the two groups were accessed by Hamilton anxiety scale（HAMA） and treatment emergent symptom scale （TESS） before and 1 weeks, 2 weeks, 4 weeks, 6 weeks after the treatment. Results There were significant differences of the total score and deducted scores of HAMA between two groups by the end of 2 weeks ,4 weeks and 6 weeks. The recovery rate and the effective rate between groups performed significant differences. No significant difference of adverse effects was found in the two groups. Conclusion The effect of venlafaxine combined with quetiapine is better than venlafaxine alone in treatment of anxiety disorder.